endovascular.es

Título: QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon
Fecha: 05-01-2016

SINGAPORE, Jan. 5, 2016 /PRNewswire/ -- QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.

Speaking at the annual Transcatheter Cardiovascular Therapeutics conference held in San Francisco in October 2015, Dr. Jihad Mustapha of Metro Hospital in Wyoming, Michigan, presented the initial acute and 30 day outcomes of the Chocolate Heart FIH study. In a group of 19 patients with de novo coronary disease, Chocolate Heart demonstrated promising early results.

Procedural Outcomes	Incidence
Bail-out (unplanned) stent placement	0% (0/19)
Significant dissection	0% (0/19)
Abrupt closure	0% (0/19)
Sub-acute occlusion	0% (0/19)
30 day Outcomes	Incidence
Death	0% (0/18)
Myocardial infarction	0% (0/18)
Target lesion revascularization	0% (0/18)
Overall major adverse cardiac events (MACE)	0% (0/18)

"While this is an early feasibility study and larger confirmatory studies will be needed, these preliminary results are very encouraging as they hint at the possibility of being able to offer an effective treatment to patients with de novo coronary disease without the use of a permanent implant, such as a metallic stent or a bioresorbable scaffold, which may take years to dissolve", stated Professor Bruno Scheller of the University of Saarland in Homburg/Saar, Germany. "The gentle dilatation of the Chocolate platform may account for these excellent early outcomes. I am looking forward to seeing the mid- and long-term outcomes with this unique device."

At the 6 month follow up time point, the core-lab adjudicated average late lumen loss (LLL) in the first 15 patients was only 0.02mm. Consistent with this low average LLL, only a single patient required an additional procedure at the treated site. "We are delighted with these results as they are consistent with the outcomes of drug-coated Chocolate in peripheral vessels," commented Eitan Konstantino, Ph.D, Chief Executive Officer of QT Vascular. "The low trauma mechanism of the Chocolate platform combined with our proprietary paclitaxel coating may offer some patients suffering from coronary artery disease an alternative to the placement of metallic stents or bioresorbable scaffolds."

The Chocolate Heart FIH study is a single-center, feasibility study conducted at CECANOT Hospital in Santo Domingo, Dominican Republic for up to 30 patients with symptomatic, de novo coronary disease. The primary endpoint is target lesion late lumen loss at 6 months (to be assessed by the independent angiographic core lab at Yale University). Secondary endpoints include device, lesion, and procedural success, abrupt closure, threatened closure, and the cross-over rate to stenting due to unsuccessful angioplasty. Patients will also undergo intra-vascular ultrasound (IVUS) assessment at 6 months (reviewed by the independent IVUS core lab at Cardiovascular Research Center in Sao Paolo, Brazil).

Drug-coated PTA balloons represent a new category of device that combines the mechanical dilatation of a balloon catheter with the biological effect of a drug to treat occluded arteries. These devices have been available for several years in Europe and were recently approved in the United States. Since their approval in the U.S., adoption has been increasing and CMS (Centers for Medicare and Medicaid Services) has granted additional reimbursement for these devices. According to some analyst estimates1, revenues for drug-coated balloons are expected to reach $1 billion by 2020.

The QT Vascular Chocolate Touch Drug Coated Peripheral Balloon received CE mark approval in July 2015. Commercial launch of Chocolate Touch in countries that are accepting CE mark will commence early this year. The product is not approved for use in the United States and CE mark does not constitute such approval.

1. Morningstar, July 30, 2015

About QT Vascular Ltd. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("QT Vascular" or the "Group"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("TriReme Medical"), based in Pleasanton, California. TriReme Medical's range of percutaneous transluminal angioplasty ("PTA") and percutaneous transluminal coronary angioplasty ("PTCA") products include (i) Chocolate® PTA Balloon Catheter, (ii) Chocolate® PTCA Balloon Catheter, (iii) GliderXtreme™ PTA Balloon Catheter, (iv) GliderfleX® PTA Balloon Catheter and (v) Glider™ PTCA Balloon Catheter, all of which have the CE Mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme™ PTA Balloon Catheter has the regulatory clearance in China and Japan, while the Glider™ PTCA Balloon Catheter has the regulatory clearance inJapan. These products are sold mainly through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Cardinal Health, Inc.), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

For more information, please visit the company website at www.qtvascular.com

SOURCE QT Vascular Ltd.

endovasculares.es